Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including...
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
Dimensions has launched its new international plant medicine retreat series in Jamaica.
Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.
The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) has confirmed it has now fully enroled its Phase III trial of MDMA-assisted therapy for PTSD.
The largest ketamine therapy provider in the US, KWC, has announced the introduction of NAD+ infusion therapy at six of its clinic locations.
Policy specialists PsychedelicsEUROPE and biopharma company, Mycotopia Therapies, are partnering to explore opportunities for psychedelic care on the continent.
Pharmadrug has announced it is advancing its opthalmology programme with the selection of its lead DMT analogue as a potential treatment for primary open angle glaucoma...
In vivo findings have demonstrated that the amanita muscaria extract – AME-1 – indicate a potential priming effect on the immune system, allowing it to more...